Home LiteratureArticle Details
PMID: 17063271 Published · ppublish English

Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.

Breast cancer research and treatment ·Vol. 103 ·No. 1 ·2007-09-19

Gutiérrez-Enríquez Sara, de la Hoya Miguel, Martínez-Bouzas Cristina, Sanchez de Abajo Ana, Ramón y Cajal Teresa, Llort Gemma, Blanco Ignacio, Beristain Elena, Díaz-Rubio Eduardo, Alonso Carmen, Tejada María-Isabel, Caldés Trinidad, Diez Orland

Abstract

Germ-line mutations in BRCA1 and BRCA2 are responsible for about 30-60% of the hereditary breast and ovarian cancer (HBOC). A large number of point mutations have been described in both genes. However, large deletions and duplications that disrupt one or more exons are overlooked by point mutation detection approaches. Over the past years several rearrangements have been identified in BRCA1, while few studies have been designed to screen this type of mutations in BRCA2. Our aim was to estimate the prevalence of large genomic rearrangements in the BRCA2 gene in Spanish breast/ovarian cancer families. The multiplex ligation-dependent probe amplification (MLPA) was employed to search gross deletions or duplications of BRCA2 in 335 Spanish moderate to high-risk breast/ovarian cancer families previously screened negative for point mutations by conventional methods. Four different and novel large genomic alterations were consistently identified by MLPA in five families, respectively: deletions of exon 2, exons 10-12 and exons 15-16 and duplication of exon 20 (in two families). RT-PCR experiments confirmed the deletion of exons 15-16. All patients harbouring a genomic rearrangement were members of high-risk families, with three or more breast/ovarian cancer cases or the presence of breast cancer in males. We provide evidence that the BRCA2 rearrangements seem to account for a relatively small proportion of familial breast cancer cases in Spanish population. The screening for these alterations as part of the comprehensive genetic testing can be recommended, especially in multiple case breast/ovarian families and families with male breast cancer cases.

Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
Published
2007-09-19
Indexed
2007-04-24
Updated
2009-11-19
Language
English
Country/Region
Netherlands
NLM ID
8111104
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com